Novartis Ag (NVS) Profit After Tax Growth (1y) (2010 - 2025)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
PAT Growth (1y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
168.07% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
-52.40% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
-45.93% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-183.48% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
5.14% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
53.69% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-8.70% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
8.77% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Jun 30, 2025 |
23.97% |
| Dec 31, 2024 |
28.69% |
| Jun 30, 2024 |
40.09% |
| Dec 31, 2023 |
17.81% |
| Jun 30, 2023 |
-54.47% |
| Mar 31, 2023 |
-12.77% |
| Dec 31, 2022 |
-20.99% |
| Sep 30, 2022 |
-9.19% |
| Jun 30, 2022 |
-14.97% |
| Mar 31, 2022 |
15.76% |
| Dec 31, 2021 |
22.62% |
| Sep 30, 2021 |
6.29% |
| Jun 30, 2021 |
6.88% |
| Mar 31, 2021 |
164.95% |
| Jun 30, 2020 |
165.53% |
| Mar 31, 2020 |
-61.12% |
| Jun 30, 2019 |
-72.71% |
| Mar 31, 2019 |
-20.41% |
| Dec 31, 2018 |
-5.46% |
| Sep 30, 2018 |
0.00% |
| Jun 30, 2018 |
290.50% |
| Mar 31, 2018 |
19.89% |
| Dec 31, 2017 |
-45.19% |
| Sep 30, 2017 |
11.17% |
| Jun 30, 2017 |
253.39% |
| Mar 31, 2017 |
182.70% |
| Dec 31, 2016 |
150.27% |
| Sep 30, 2016 |
242.86% |
| Mar 31, 2016 |
35,645,438.73% |
| Dec 31, 2015 |
67,631,003.07% |
| Sep 30, 2015 |
27,353,363.59% |
| Mar 31, 2015 |
0.97% |
| Sep 30, 2012 |
-0.19% |
| Jun 30, 2012 |
7.31% |
| Mar 31, 2012 |
-26.09% |
| Dec 31, 2011 |
-100.00% |
| Sep 30, 2011 |
-12.78% |
| Jun 30, 2011 |
-100.00% |
| Mar 31, 2011 |
-75.81% |
| Dec 31, 2010 |
-2.50% |
| Sep 30, 2010 |
-70.74% |
| Jun 30, 2010 |
15.75% |
| Mar 31, 2010 |
49.27% |
